| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CPB2 |
| Uniprot No | Q96IY4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-423aa |
| 氨基酸序列 | MKLCSLAVLV PIVLFCEQHV FAFQSGQVLA ALPRTSRQVQ VLQNLTTTYE IVLWQPVTAD LIVKKKQVH FFVNASDVDN VKAHLNVSGI PCSVLLADVE DLIQQQISND TVSPRASASY YEQYHSLNE IYSWIEFITE RHPDMLTKIH IGSSFEKYPL YVLKVSGKEQ AAKNAIWIDC GIHAREWIS PAFCLWFIGH ITQFYGIIGQ YTNLLRLVDF YVMPVVNVDG YDYSWKKNRM WRKNRSFYA NNHCIGTDLN RNFASKHWCE EGASSSSCSE TYCGLYPESE PEVKAVASFL RRNINQIKA YISMHSYSQH IVFPYSYTRS KSKDHEELSL VASEAVRAIE KTSKNTRYTH GHGSETLYL APGGGDDWIY DLGIKYSFTI ELRDTGTYGF LLPERYIKPT CREAFAAVSK IAWHVIRNV |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CPB2(羧肽酶B2/TAFI)重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*"Recombinant human carboxypeptidase B2 (TAFI) inhibits inflammatory responses in endothelial cells"*
**作者**：Smith A, et al.
**摘要**：本研究通过大肠杆菌表达系统成功制备了重组人CPB2蛋白，并证明其可通过抑制缓激肽降解减轻内皮细胞炎症反应，提示其在调节血管通透性中的潜在作用。
2. **文献名称**：*"Crystal structure of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) provides insights into enzymatic regulation"*
**作者**：Tanaka Y, et al.
**摘要**：作者解析了重组TAFIa(活化CPB2)的晶体结构，揭示了其底物结合域的关键氨基酸残基，为设计调控纤溶系统的药物提供了结构基础。
3. **文献名称**：*"Expression and functional characterization of a novel truncated isoform of carboxypeptidase B2 in hepatocellular carcinoma"*
**作者**：Li X, et al.
**摘要**：该研究在哺乳动物细胞中表达了肝癌相关的CPB2截短型重组蛋白，发现其异常表达与肿瘤血管生成相关，可能成为癌症治疗的生物标志物。
注：以上文献信息为示例性质，实际文献需通过学术数据库检索。建议使用关键词**"CPB2 recombinant"**或**"TAFI expression"**在PubMed/Google Scholar查找最新研究。
**Background of CPB2 Recombinant Protein**
Carboxypeptidase B2 (CPB2), also known as thrombin-activatable fibrinolysis inhibitor (TAFI), is a plasma glycoprotein that plays a critical role in regulating fibrinolysis and inflammation. Discovered in the 1990s, CPB2 is synthesized in the liver as an inactive zymogen (pro-CPB2) and circulates in the bloodstream. It is activated by proteolytic cleavage, primarily by thrombin in complex with thrombomodulin, converting it into TAFIa. TAFIa modulates clot stability by removing C-terminal lysine residues from fibrin, thereby reducing plasminogen binding and attenuating fibrinolysis.
The CPB2 gene is located on chromosome 13q14.11 and exhibits genetic polymorphisms linked to variable plasma TAFI levels, influencing thrombotic and bleeding disorders. Dysregulation of CPB2 activity is associated with pathological conditions, including deep vein thrombosis, cardiovascular diseases, and inflammatory syndromes.
Recombinant CPB2 proteins are engineered using expression systems (e.g., mammalian or bacterial cells) to produce functional or mutant forms for research and therapeutic exploration. These proteins enable mechanistic studies on fibrinolysis, structure-function analyses, and drug development targeting TAFIa for anticoagulant therapies. Additionally, recombinant CPB2 serves as a tool to investigate its emerging roles in tissue repair, cancer progression, and immune modulation.
In summary, CPB2 recombinant protein is pivotal for understanding hemostasis and developing interventions for thrombosis-related diseases, bridging molecular biology with clinical applications.
×
